Risankizumab Therapy for Moderate-to-Severe Psoriasis—A Multi-Center, Long-Term, Real-Life Study from Poland

Abstract

The present multi-center, long-term, real-life study made an attempt to assess the efficacy of risankizumab in the treatment of moderate-to-severe plaque psoriasis. The study comprised 185 patients from 10 Polish dermatologic departments undergoing risankizumab treatment. The disease severity was measured using the Psoriasis Area and Severity Index (PASI) before the start of the risankizumab treatment and next at the defined timepoints, i.e., 4, 16, 28, 40, 52 and 96 weeks of treatment. The percentage of patients achieving PASI90 and PASI100 responses as well as the PASI percentage decrease at the defined timepoints were calculated, and correlations with clinical characteristics and therapeutic effect were analyzed. The number of patients evaluated at the defined timepoints was: 136, 145, 100, 93, 62, and 22 at 4, 16, 28, 40, 52 and 96 weeks of treatment, respectively. At 4, 16, 28, 40, 52 and 96 weeks, the PASI90 response was achieved in 13.2%, 81.4%, 87.0%, 86.0%, 88.7% and 81.8% of patients, whereas the PASI100 response was achieved in 2.9%, 53.1%, 67.0%, 68.8%, 71.0% and 68.2% of patients, respectively. Our study revealed a significant negative correlation between a decrease in the PASI and the presence of psoriatic arthritis as well as the patient’s age and duration of psoriasis at several timepoints throughout the observation period.

Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)

“…Similar effectiveness, regardless of BMI, has also been observed for the other two IL-23 inhibitors [20,21]. However, the presence of at least one CMD in our study was a predictor of lower response to the treatment at weeks 16, 28, 52, and 104, with comparable results to those observed by Adamczyk et al [22].…”

“…In the multivariate analysis, the involvement of difficult-to-treat areas was associated with lower effectiveness in the short term, as expected. However, from week 52 onwards, these differences were no longer recorded, except for PASI100 at week 52, which could be explained by a minimal residual PASI in these areas [13,19,22]. In our study, risankizumab was rapidly effective, particularly in patients with genital psoriasis, which improved patient well-being [23].…”

2‐Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy

“…Te current real-life literature only partially aligns with our fndings. Several real-life studies have reported that BMI, psoriatic arthritis, and previous biologic failure may be associated with a reduced treatment response [7,[14][15][16]. In contrast, other studies did not fnd this correlation [8,17,18], which confrms our data and suggests that risankizumab could be used also in special categories of patients with unfavorable characteristics, such as obese, multitreated ones, or those with very severe disease.…”

“…Tese data have been confrmed by several real-world studies [5,6]. However, the majority of these reports described the short-term efectiveness of risankizumab, and to date, data about the long term are scarce [7][8][9].…”

A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS)

“…7 In our experience, the bio-naive status was independently associated with better responses throughout the study period, consistent with other experiences on IL-23 inhibitors. [8][9][10] This study has a few limitations, being its retrospective nature and the heterogeneity of clinical evaluations from different clinicians. However, its main strengths are the large sample size and the extended follow-up, along with the analysis of the subpopulations of patients with a recent history of psoriasis.…”